CA
NZ
UK
AU
IND
US
…
Seer, Inc., a life sciences company, develops and commercializes products to decode the biology of the proteome to improve human health in the United States, China, Australia, Europe, Israel, Japan, and South Africa. The company offers Proteograph Product Suite, an integrated solution, which includes proprietary engineered nanoparticles, consumables, automation instrumentation, and data analysis software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. The company also offers Proteograph ONE, a third-generation assay; Proteograph DIRECT, which provides an automated approach for direct digestion of samples for bottom-up LC-MS proteomic analysis; and Proteograph Analysis Suite, a data analytics software suite designed to support quality control, data management, and interpretation of Proteograph output which is currently offered as a cloud-based solution. It markets and sells its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Seer Inc develops a proteomics platform to measure proteins at scale for research and drug development. Growth may be supported by wider adoption of proteomics in biopharma and diagnostics and by recurring consumables and service revenue, which could appeal to investors seeking exposure to a technology-led life sciences tools provider.
Key risks include early commercial stage, ongoing losses and cash burn, competition from established proteomics and mass-spectrometry players, uncertain adoption and scalability, and potential dilution from future financing.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -73.40M | -86.50M | -86.28M | -92.97M | -71.17M |
| Net income | -73.60M | -86.60M | -86.28M | -88.70M | -68.63M |
| Selling general administrative | 42.58M | 56.57M | 60.50M | 58.53M | 45.76M |
| Gross profit | 8.01M | 6.83M | 1.45M | 6.74M | 3.19M |
| Reconciled depreciation | 6.10M | 6.18M | 5.10M | 3.94M | 2.56M |
| Ebit | -77.99M | -86.50M | -86.28M | -97.23M | -71.47M |
| Ebitda | -71.89M | -80.33M | -80.70M | -92.97M | -71.15M |
| Depreciation and amortization | 6.10M | 6.18M | 5.58M | 4.27M | 0.33M |
| Non operating income net other | - | - | - | 4.27M | 0.33M |
| Operating income | -77.99M | -100.10M | -104.94M | -97.23M | -71.47M |
| Other operating expenses | 94.11M | 114.05M | 120.12M | 111.92M | 77.87M |
| Interest expense | - | - | - | 0.33M | 0.02M |
| Tax provision | 0.20M | 0.10M | 0.00M | - | - |
| Interest income | 11.52M | 16.67M | 15.54M | 4.60M | 0.33M |
| Net interest income | 11.52M | 16.67M | 15.54M | 4.60M | 0.30M |
| Income tax expense | 0.20M | 0.10M | 5.41M | -4.27M | -2.54M |
| Total revenue | 16.12M | 13.95M | 15.18M | 14.69M | 6.39M |
| Total operating expenses | 86.00M | 106.93M | 106.39M | 103.98M | 74.66M |
| Cost of revenue | 8.11M | 7.12M | 13.73M | 7.94M | 3.21M |
| Total other income expense net | 4.59M | 13.60M | 18.66M | 4.27M | 0.30M |
| Net income from continuing ops | -73.60M | -86.60M | -91.00M | -92.97M | -71.17M |
| Net income applicable to common shares | - | - | - | -92.97M | -71.17M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 296.08M | 366.60M | 436.27M | 487.93M | 539.14M |
| Other current assets | 1.89M | 3.25M | 3.08M | 2.10M | 3.34M |
| Total liab | 36.78M | 39.03M | 39.37M | 40.94M | 36.22M |
| Total stockholder equity | 259.31M | 327.57M | 396.90M | 446.99M | 502.92M |
| Other current liab | 7.16M | 7.52M | 9.35M | 8.51M | 8.39M |
| Common stock | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Capital stock | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Retained earnings | -465.97M | -392.37M | -305.77M | -219.50M | -126.53M |
| Other liab | - | - | - | 0.32M | 0.34M |
| Other assets | - | - | - | 1.38M | 539.14M |
| Cash | 47.28M | 40.75M | 32.50M | 53.21M | 232.81M |
| Total current liabilities | 15.69M | 15.33M | 13.22M | 12.58M | 13.42M |
| Current deferred revenue | 0.34M | 0.41M | 0.21M | 0.13M | 0.38M |
| Net debt | -23.63M | -14.79M | -4.24M | -23.33M | -209.49M |
| Short term debt | 2.58M | 2.31M | 2.29M | 1.84M | 0.86M |
| Short long term debt total | 23.65M | 25.96M | 28.26M | 29.87M | 23.32M |
| Other stockholder equity | 724.82M | 719.80M | 702.87M | 667.74M | 629.98M |
| Property plant equipment | - | - | - | 19.41M | 33.23M |
| Total current assets | 201.53M | 253.32M | 330.51M | 434.98M | 411.70M |
| Long term investments | 54.69M | 63.10M | 56.86M | 5.16M | 93.19M |
| Net tangible assets | - | - | - | 446.99M | 502.92M |
| Short term investments | 138.61M | 195.66M | 283.73M | 368.03M | 167.26M |
| Net receivables | 5.95M | 6.23M | 6.72M | 7.02M | 4.14M |
| Inventory | 7.79M | 7.44M | 4.49M | 4.63M | 4.14M |
| Accounts payable | 5.61M | 4.62M | 1.37M | 2.10M | 3.79M |
| Accumulated other comprehensive income | 0.46M | 0.14M | -0.19M | -1.25M | -0.54M |
| Common stock total equity | - | - | - | 0.00M | 0.00M |
| Retained earnings total equity | - | - | - | -219.50M | -126.53M |
| Non currrent assets other | 4.62M | 8.80M | 1.00M | 1.38M | 1.02M |
| Non current assets total | 94.55M | 113.27M | 105.76M | 52.95M | 127.44M |
| Capital lease obligations | 23.65M | 25.96M | 28.26M | 29.87M | 23.32M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | 62.70M | 65.86M | 29.08M | -112.62M | -163.96M |
| Change to liabilities | - | - | - | -1.30M | 3.75M |
| Total cashflows from investing activities | 61.55M | 65.86M | 37.90M | -122.72M | -170.88M |
| Total cash from financing activities | -10.57M | -11.49M | 0.45M | 3.89M | 116.63M |
| Change to operating activities | - | - | - | -2.19M | -1.50M |
| Net income | -73.60M | -86.60M | -86.28M | -92.97M | -71.17M |
| Change in cash | 6.53M | 8.25M | -20.71M | -179.60M | -100.59M |
| Begin period cash flow | 41.28M | 33.02M | 53.73M | 233.34M | 333.93M |
| End period cash flow | 47.81M | 41.28M | 33.02M | 53.73M | 233.34M |
| Total cash from operating activities | -44.45M | -46.11M | -59.06M | -60.78M | -46.35M |
| Issuance of capital stock | - | - | - | 0.00M | 102.96M |
| Depreciation | 7.25M | 6.18M | 5.58M | 3.94M | 2.56M |
| Other cashflows from investing activities | -1.30M | 0.34M | - | 0.17M | - |
| Change to inventory | -2.90M | -2.67M | -1.95M | -1.59M | -3.59M |
| Change to account receivables | 0.28M | 0.49M | 0.30M | -1.82M | -2.50M |
| Sale purchase of stock | -10.20M | -11.82M | -0.01M | -0.02M | -0.04M |
| Other cashflows from financing activities | -0.83M | 0.32M | 0.47M | 0.78M | 13.71M |
| Change to netincome | - | - | - | 34.51M | 25.93M |
| Capital expenditures | 1.80M | 3.58M | 7.31M | 10.27M | 6.92M |
| Change receivables | - | - | - | -2.87M | -3.88M |
| Cash flows other operating | - | - | - | 0.33M | -1.13M |
| Cash and cash equivalents changes | - | - | - | -179.60M | -100.59M |
| Change in working capital | -0.58M | -0.14M | -2.72M | -7.39M | -5.87M |
| Stock based compensation | 15.41M | 28.21M | 34.42M | 33.67M | 25.93M |
| Other non cash items | 7.07M | 6.25M | -10.07M | 1.97M | 1.00M |
| Free cash flow | -46.24M | -49.69M | -66.37M | -71.05M | -53.27M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| SEER Seer Inc |
0.01 0.58% |
1.74 | - | - | 7.40 | 0.47 | 0.08 | 1.72 |
| NVO Novo Nordisk A/S |
-0.11 0.27% |
40.34 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-16.25 2.94% |
536.90 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
9.79 1.02% |
971.05 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Seer, Inc., a life sciences company, develops and commercializes products to decode the biology of the proteome to improve human health in the United States, China, Australia, Europe, Israel, Japan, and South Africa. The company offers Proteograph Product Suite, an integrated solution, which includes proprietary engineered nanoparticles, consumables, automation instrumentation, and data analysis software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. The company also offers Proteograph ONE, a third-generation assay; Proteograph DIRECT, which provides an automated approach for direct digestion of samples for bottom-up LC-MS proteomic analysis; and Proteograph Analysis Suite, a data analytics software suite designed to support quality control, data management, and interpretation of Proteograph output which is currently offered as a cloud-based solution. It markets and sells its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.
| Name | Title | Year Born |
|---|---|---|
| Dr. Omid C. Farokhzad M.D., Ph.D. | Founder, Pres, CEO & Chair of the Board of Directors | 1969 |
| Mr. David R. Horn | Exec. VP, Treasurer & CFO | 1968 |
| Ms. Elona Kogan Esq., J.D. | Gen. Counsel & Sec. | 1969 |
| Mr. Joe Laws | Chief Technology Officer and Co-Founder | NA |
| Kenny Ross | Chief Operations & Product Officer | NA |
| Ms. Karen Possemato | Chief Marketing Officer | NA |
| Ms. Marissa Dixon | Chief People Officer | NA |
| Dr. Serafim Batzoglou Ph.D. | Chief Data Officer | NA |
| Mr. Martin Goldberg Ph.D. | Sr. VP of Devel. | NA |
| Mr. Scott D. Thomas | Chief Commercial Officer | 1973 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-0.09%
Communication Services
+0.51%
Consumer Cyclical
-0.11%
Consumer Defensive
-0.44%
Energy
-0.15%
Financial Services
-0.04%
Financials
+0.43%
Healthcare
+0.73%
Industrials
+0.57%
Real Estate
-0.32%
Technology
+1.29%
Utilities
+0.10%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...